Items tagged with Pharma industry

Otsuka and R-Pharm announce licensing agreement to commercialize Deltyba™ in Russia and CIS countries (post)

Otsuka Pharmaceutical Co. Ltd. (Otsuka) and the Russian pharmaceutical company R-Pharm JSC (R-Pharm) have entered into a licensing agreement to manufacture and commercialize Deltyba™ (delamanid) for the treatment of adults with pulmonary multidrug-resistant tuberculosis (MDR-TB) in the Russian Federation and the Commonwealth of Independent States (CIS).

WHO prequalifies Mylan's India unit to supply TB drug API (post)

The WHO has prequalified Indian-based Mylan Laboratories Ltd to supply the tuberculosis drug ingredient protionamide.

New TB drug making its way to India and Russia (post)

TOKYO -- With tuberculosis killing 1.67 million people every year, Otsuka Pharmaceutical is expediting deliveries of a new drug called Delamanid to India and other developing countries that are desperate for a cure.

Superbugs: first independent comparison of pharma companies’ efforts to address drug-resistant infections (post)

The Benchmark compares how a cross-section of the pharmaceutical industry is responding to the threat from drug-resistant infections. It measures the 30 most active players in antimicrobial development and production and includes multinational pharmaceutical companies, biotechnology firms and manufacturers of generic medicines.

Report shows life sciences industry alliance is taking action to curb antimicrobial resistance, with more to come (post)

Otsuka to advance development of novel TB compound (post)

Otsuka awarded grant to advance development of novel TB compound OPC-167832 with delamanid

Novartis drops antibiotics research program, ceasing work on several experimental antimicrobial projects (post)

2018 Access to Medicine Index (post)

The 2018 Access to Medicine Index finds that a handful of pharmaceutical companies are developing the bulk of urgently needed new medicines for the poor.

Olainfarm will supply TB drugs to WHO for more than 1 million dollars (post)

Based on a cooperation agreement concluded last year, in the 1st quarter of 2019 JSC Olainfarm will be delivering its PAS-sodium anti-tuberculosis medicine, to the World Health Organisation (WHO) for a total of more than 1 million U.S. dollars. PAS-sodium is a widely known tuberculosis treatment drug that has proven its effectiveness globally, and the WHO is using it to treat tuberculosis in developing countries throughout Asia and Africa.

New study from Access to Medicine Foundation analyses 10 years of data on pharma companies and access to medicine (post)

In a new report the Access to Medicine Foundation shows where pharmaceutical companies have made progress in the past ten years when it comes to access to medicine. It analyses companies’ performances in 106 low- and middle-income countries – home to 83% of all people alive today.